1946-6536
No
HUM GENE THER METHOD
0
31
UNITED STATES
http://online.liebertpub.com/hgtb
>12周,或約稿審稿時(shí)間
容易平均錄用比例
2.089影響因子
生物工程與應(yīng)用微生物小學(xué)科
《人類(lèi)基因治療》是一本涵蓋基因治療各個(gè)方面的多學(xué)科雜志。該雜志通過(guò)提供最新的研究和技術(shù)突破,對(duì)DNA、RNA和細(xì)胞療法進(jìn)行了深入報(bào)道。人類(lèi)基因治療為科學(xué)和臨床信息提供了一個(gè)中心論壇,包括倫理、法律、監(jiān)管、社會(huì)和商業(yè)問(wèn)題,使治療程序的進(jìn)步和進(jìn)步能夠改善患者的結(jié)果,并最終治愈疾病。該期刊分為三個(gè)部分。人類(lèi)基因療法是其旗艦,每年出版12期?!禜GT Methods》是一本雙月刊,主要研究基因治療在產(chǎn)品檢測(cè)和開(kāi)發(fā)中的應(yīng)用。HGT臨床發(fā)展是一份季刊,作為發(fā)布與細(xì)胞和基因治療產(chǎn)品的監(jiān)管審查和商業(yè)開(kāi)發(fā)相關(guān)的數(shù)據(jù)的場(chǎng)所。完整的覆蓋范圍包括:向量發(fā)展的改善運(yùn)載系統(tǒng)細(xì)胞療法小型核酸療法,包括RNAi臨床試驗(yàn)和動(dòng)物模型臨床協(xié)議臨床前動(dòng)物和體外研究評(píng)估用于支持臨床應(yīng)用的基因和細(xì)胞治療產(chǎn)品的安全性臨床試驗(yàn),包括結(jié)果證實(shí)性或陰性的臨床試驗(yàn)與基因和細(xì)胞治療產(chǎn)品的商業(yè)開(kāi)發(fā)相關(guān)的熱點(diǎn)問(wèn)題
http://mc.manuscriptcentral.com/hum
Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.The Journal is divided into three parts. Human Gene Therapy, the flagship, is published 12 times per year. HGT Methods, a bimonthly journal, focuses on the applications of gene therapy to product testing and development. HGT Clinical Development, a quarterly journal, serves as a venue for publishing data relevant to the regulatory review and commercial development of cell and gene therapy products.Complete coverage includes: Improvements in vector developments Delivery systems Cell therapy Small nucleic acid therapeutics, including RNAi Clinical trials and animal models Clinical protocols Pre-clinical animal and in vitro studies to assess the safety of gene and cell therapy products used to support clinical applications Clinical trials including those in which the results are confirmatory or negative Topical issues related to the commercial development of gene and cell therapy products
快速預(yù)審、投刊前指導(dǎo)、專(zhuān)業(yè)學(xué)術(shù)評(píng)審,對(duì)文章進(jìn)行評(píng)價(jià);
立即咨詢(xún)校對(duì)編輯、深度潤(rùn)色,讓稿件符合學(xué)術(shù)規(guī)范,格式體例等標(biāo)準(zhǔn);
立即咨詢(xún)適用于語(yǔ)句和結(jié)構(gòu)尚需完善和調(diào)整的中文文章,確保稿件達(dá)到要求;
立即咨詢(xún)數(shù)據(jù)庫(kù)包括:期刊、文章、書(shū)籍、會(huì)議、預(yù)印書(shū)、百科全書(shū)和摘要等;
立即咨詢(xún)讓作者在期刊選擇時(shí)避免走彎路,縮短稿件被接收的周期;
立即咨詢(xún)根據(jù)目標(biāo)期刊格式要求對(duì)作者文章進(jìn)行全面的格式修改和調(diào)整;
立即咨詢(xún)幫助作者將稿件提交至目標(biāo)期刊投稿系統(tǒng),降低退稿或拒稿率;
立即咨詢(xún)按照您提供的稿件內(nèi)容,指導(dǎo)完成投稿附信(cover letter);
立即咨詢(xún)大類(lèi)學(xué)科同領(lǐng)域優(yōu)質(zhì)期刊 | 大類(lèi)學(xué)科 | 小類(lèi)學(xué)科 | 影響因子 | 分區(qū) | ISSN |
---|---|---|---|---|---|
BIOMARKERS | 醫(yī)學(xué) | 生物工程與應(yīng)用微生物 | 1.73 | 4區(qū) | 1354-750X |
BIOPHARM INTERNATIONAL | 醫(yī)學(xué) | 生物工程與應(yīng)用微生物 | 0.263 | N/A | 1542-166X |
CANCER GENE THERAPY | 醫(yī)學(xué) | 生物工程與應(yīng)用微生物 | 4.681 | N/A | 0929-1903 |
ENERGY EDUC SCI TECH | 醫(yī)學(xué) | 生物工程與應(yīng)用微生物 | N/A | 2區(qū) | 1465-3249 |
DISEASE MARKERS | 醫(yī)學(xué) | 生物工程與應(yīng)用微生物 | 2.761 | 3區(qū) | 0278-0240 |
EXPERT OPINION ON BIOLOGICAL THERAPY | 醫(yī)學(xué) | 生物工程與應(yīng)用微生物 | 3.585 | 3區(qū) | 1471-2598 |
GENETIC COUNSELING | 醫(yī)學(xué) | 生物工程與應(yīng)用微生物 | N/A | N/A | 1015-8146 |
HUMAN GENE THERAPY | 醫(yī)學(xué) | 生物工程與應(yīng)用微生物 | 3.855 | 2區(qū) | 1043-0342 |
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS | 醫(yī)學(xué) | 生物工程與應(yīng)用微生物 | 1.767 | N/A | 0393-6155 |
JOURNAL OF ANTIBIOTICS | 醫(yī)學(xué) | 生物工程與應(yīng)用微生物 | 2.446 | N/A | 0021-8820 |
發(fā)現(xiàn)心儀選題請(qǐng)?zhí)顔?/b>
獲取發(fā)表周期短、審稿速度快容易錄用的期刊